Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Good momentum in commercial CDMO business
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity
Subscribe To Our Newsletter & Stay Updated
